$303.53 Million in Sales Expected for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) This Quarter

Equities analysts forecast that Neurocrine Biosciences, Inc. (NASDAQ:NBIXGet Rating) will report $303.53 million in sales for the current fiscal quarter, according to Zacks Investment Research. Eleven analysts have issued estimates for Neurocrine Biosciences’ earnings, with the lowest sales estimate coming in at $286.31 million and the highest estimate coming in at $323.00 million. Neurocrine Biosciences reported sales of $236.60 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 28.3%. The firm is expected to report its next earnings results before the market opens on Monday, January 1st.

On average, analysts expect that Neurocrine Biosciences will report full year sales of $1.37 billion for the current year, with estimates ranging from $1.32 billion to $1.44 billion. For the next financial year, analysts expect that the company will post sales of $1.63 billion, with estimates ranging from $1.52 billion to $1.76 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Neurocrine Biosciences.

Neurocrine Biosciences (NASDAQ:NBIXGet Rating) last announced its earnings results on Friday, February 11th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.61 by ($0.69). Neurocrine Biosciences had a net margin of 7.90% and a return on equity of 6.89%. The company had revenue of $312.00 million during the quarter, compared to analyst estimates of $317.72 million. During the same quarter last year, the business earned $3.58 EPS. The firm’s revenue for the quarter was up 25.9% compared to the same quarter last year.

NBIX has been the topic of a number of recent research reports. The Goldman Sachs Group upgraded shares of Neurocrine Biosciences from a “neutral” rating to a “buy” rating and set a $115.00 price target on the stock in a research report on Thursday, February 24th. Zacks Investment Research lowered shares of Neurocrine Biosciences from a “hold” rating to a “strong sell” rating in a research report on Thursday, April 14th. Piper Sandler lowered shares of Neurocrine Biosciences from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $114.00 to $94.00 in a research report on Thursday, March 3rd. JPMorgan Chase & Co. boosted their price target on shares of Neurocrine Biosciences from $125.00 to $126.00 and gave the stock an “overweight” rating in a research report on Monday, April 4th. Finally, Jefferies Financial Group lowered shares of Neurocrine Biosciences to a “hold” rating and set a $94.00 price target on the stock. in a research report on Thursday, March 3rd. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $111.17.

In other news, Director William H. Rastetter sold 10,728 shares of the business’s stock in a transaction that occurred on Friday, April 1st. The shares were sold at an average price of $94.93, for a total value of $1,018,409.04. Following the sale, the director now directly owns 34,022 shares of the company’s stock, valued at approximately $3,229,708.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stephen A. Sherwin sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, January 24th. The stock was sold at an average price of $74.43, for a total transaction of $1,116,450.00. The disclosure for this sale can be found here. Insiders sold a total of 46,743 shares of company stock worth $3,957,821 over the last three months. Insiders own 4.30% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its stake in Neurocrine Biosciences by 0.8% during the 3rd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 17,487 shares of the company’s stock worth $1,677,000 after buying an additional 136 shares during the period. Whittier Trust Co. increased its stake in Neurocrine Biosciences by 102.8% during the 4th quarter. Whittier Trust Co. now owns 290 shares of the company’s stock worth $25,000 after buying an additional 147 shares during the period. Cubist Systematic Strategies LLC grew its holdings in Neurocrine Biosciences by 0.7% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 22,275 shares of the company’s stock worth $2,136,000 after acquiring an additional 159 shares in the last quarter. Asset Management One Co. Ltd. grew its holdings in Neurocrine Biosciences by 0.4% during the 3rd quarter. Asset Management One Co. Ltd. now owns 39,215 shares of the company’s stock worth $3,761,000 after acquiring an additional 166 shares in the last quarter. Finally, Daiwa Securities Group Inc. grew its holdings in Neurocrine Biosciences by 1.6% during the 3rd quarter. Daiwa Securities Group Inc. now owns 10,817 shares of the company’s stock worth $1,038,000 after acquiring an additional 174 shares in the last quarter. 95.93% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ NBIX opened at $97.78 on Wednesday. The company’s 50-day simple moving average is $91.91 and its 200-day simple moving average is $89.13. Neurocrine Biosciences has a 52-week low of $71.88 and a 52-week high of $108.01. The firm has a market cap of $9.34 billion, a price-to-earnings ratio of 107.45, a price-to-earnings-growth ratio of 4.74 and a beta of 0.71. The company has a quick ratio of 3.83, a current ratio of 3.96 and a debt-to-equity ratio of 0.24.

Neurocrine Biosciences Company Profile (Get Rating)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

See Also

Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.